As tumor suppressor CHEK2 is widely accepted as a driver gene during tumorigenesis in various types of cancer, mainly in breast cancer32,33, PRR14’s inhibition of CHEK2 may explain its more powerful oncogene function in breast cancer and predict poor response to chemotherapy in PRR14-overexpressing patients. Here, CHEK2 is linked to neoplasm.